Announcement • Jun 24
Coiled Therapeutics plc Announces Appointment of Craig A. Tooman to Independent Non-Executive Director, Effective June 25, 2026
Coiled Therapeutics plc announced the appointment of Craig A. Tooman as an Independent Non-Executive Director with effect from June 25, 2026. Mr. Tooman most recently served as President, Chief Executive Officer and Board Director of Silence Therapeutics, the NASDAQ-listed siRNA company and brings over 30 years of international pharmaceutical and biotechnology leadership experience spanning clinical, operational, financial, M&A and capital markets disciplines, including more than 20 years as a public company CEO and CFO. In these executive roles and as a Board member, he directly participated in the raising of nearly USD 9 billion in capital. At Silence Therapeutics, he helped transform the business from an early-stage UK research enterprise mainly trading on AIM into a well-financed NASDAQ listed global development company with multiple assets in later-stage clinical trials, including a first-in-class treatment for polycythemia vera. Throughout his career, he has played leading roles building, financing and realising value in life-science companies, participating in the execution of numerous strategic transactions across the biotechnology sector. As President, CEO and Board Director of Aratana Therapeutics, he negotiated the company's USD 250 million merger with Elanco following Aratana Therapeutics' Bloomberg "IPO of the Year" award in 2013 and a record-setting three US regulatory approvals in a single year. As CFO of Enzon Pharmaceuticals, he coordinated the sale of its specialty pharmaceutical business to Sigma Tau for over USD 300 million, and at ILEX Oncology he led the USD 1.1 billion acquisition by Genzyme Corporation, including its integration. Earlier in his career, he held senior strategic and investor relations roles at Pharmacia, Pharmacia & Upjohn and The Upjohn Company in the US, Europe and Japan. Mr. Tooman also brings extensive board experience, having served on the Supervisory Board of CureVac N.V. from 2019 until its acquisition by BioNTech in 2025, where he chaired both the Compensation and Nomination/Governance Committees, and on the boards of Aratana Therapeutics, Verté Therapeutics, Ondine Biomedical, Insite Vision and Xanodyne Pharmaceuticals, chairing the Audit Committees of four of these companies. His deep oncology heritage, including building the most valuable oncology business in Texas (ILEX Oncology) during the period 2002-2005, for which he was awarded the first Entrepreneur in Residence (EIR) designation by the Cancer Prevention and Research Institute of Texas (CPRIT), aligns directly with Coiled Therapeutics' precision oncology focus and its lead candidate, AO-252. Craig Allen Tooman, aged 60, currently holds or has held the following directorships or partnerships in the past five years: Current: Stockbourne LLC. Past five years: Silence Therapeutics plc, Silence Therapeutics Inc, Silence Therapeutics (London) Limited, Silence Therapeutics GmbH, Innopeg Limited, CureVac N.V., Verté Therapeutics Inc., Ondine Biomedical Inc.
